Biogen Idec Inc. said that it will work with Regulus Therapeutics Inc. to identify microRNAs biomarkers in patients with multiple sclerosis.
Biogen makes and sells several multiple sclerosis drugs including Avonex and Tysabri, and it is also developing BG-12, a pill that is seen as a promising treatment for the condition. The companies said Regulus believes the biomarkers may help identify the best patients for clinical trials of multiple sclerosis drugs, could be used to develop diagnostic tests and may help monitor the progression of the illness or relapses.
MicroRNAs are small RNA molecules. RNA helps synthesize proteins in the body, and microRNA helps regulate the way genes work.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1863